JPMorgan Chase has named Sri Kosaraju as global chair of investment banking, marking the return of the former managing director who spent 16 years helping build the bank’s healthcare investment banking business. Kosaraju, most recently the CEO of biotech firm Inscripta, will work out of San Francisco and report to Filippo Gori and John Simmons, the co-heads of global banking. The appointment follows JPMorgan’s broader effort to expand its investment banking operations, including senior hires from Goldman Sachs and Deutsche Bank in 2025.
Kosaraju’s Healthcare Expertise
Sri Kosaraju is returning to JPMorgan Chase after more than two decades building a career at the intersection of finance and life sciences. Most recently, he ran biotech company Inscripta, where he led the business from 2020 as it worked to bring its CRISPR-based gene-editing technology to market. Before that, he was president and chief financial officer of Penumbra, helping steer the medical device maker through its IPO and a period of rapid growth that pushed annual revenue past $500 million.
Kosaraju’s earlier career was shaped at JPMorgan, where he spent 16 years in equity capital markets. He rose to managing director, led healthcare ECM and later co-headed technology, media and telecom ECM, advising biotech and medtech companies on stock offerings and convertible deals. Alongside his banking work, he serves on the board of 10x Genomics. A mechanical engineering graduate of Massachusetts Institute of Technology, Kosaraju brings a rare mix of scientific and capital markets experience back to the bank.
Strategic Banking Reorganisation
Kosaraju’s return follows a major shake-up at JPMorgan Chase last year, when the bank brought its commercial, corporate and investment banking operations under a single leadership structure run by Filippo Gori and John Simmons. The reorganisation was designed to give clients broader coverage and make it easier for bankers to work across businesses. As part of that push, JPMorgan has also added senior healthcare talent, including Jerry Lee as global investment banking chair for healthcare.
The strategy has helped the bank hold a leading position in dealmaking. Through December 2025, JPMorgan earned $9.44 billion in investment banking fees, equivalent to a 7.4 per cent global market share. Executives expect activity to pick up further in 2026 as technology investment accelerates and companies seek advice on navigating geopolitical and macroeconomic uncertainty. Kosaraju will be based in San Francisco, reporting to Gori and Simmons, and will play a key role in expanding the bank’s healthcare banking business.
Industry Context And Outlook
After a turbulent spring, investment banking fees still finished close to record levels in 2025. JPMorgan Chase used the year to reinforce its dealmaking bench, recruiting senior bankers from rivals Goldman Sachs and Deutsche Bank in October. Bankers point to a healthy pipeline in healthcare, biotech and medtech, with strong activity expected across both M&A and equity capital markets.
The return of Sri Kosaraju fits into a broader effort to build out the franchise. JPMorgan’s global investment banking arm is now led by co-chairs Blessing and Jay Hor, while capital markets veteran Kevin Foley oversees debt and equity issuance. On the advisory side, Anu Aiyengar has taken on a broader mergers and acquisitions remit. With fourth-quarter and full-year results due next week, executives say they are increasingly confident about dealmaking prospects heading into 2026.
Catch up on the latest global business and banking news on Inspirepreneur Magazine.
